Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical industry services provider Ergomed said it expected its full-year revenue and operating earnings to be ahead of current market expectations following a strong first half.
In the first half, revenue was expected to rise 36% to £35.0m.
'Following a strong start to the year, we are pleased to have continued performing above expectations, and again upgrade guidance for the 2019 financial year,' executive chairman Miroslav Reljanovic said.
'Ergomed is in robust shape, and we are committed to our strategy of focusing on the opportunities in specialised CRO services and pharmacovigilance.'
At 9:52am: (LON:ERGO) Ergomed Plc share price was +20p at 319p